Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas

Andrea Michelotti, Antonella Romanini, Piergiorgio Giannessi, Carmelo Bengala, Pierfranco Conte

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background. Neutropenia and infections are the dose-limiting toxicities of the EID regimen and can cause dose reduction and/or delay in chemotherapy administration. The purpose of this study was to verify if EID + G-CSF is feasible with an acceptable toxicity in a day hospital setting and if G-CSF could allow an increase in the dose intensity of the EID regimen by shortening the intervals between the courses. Patients and Methods: 20 patients with inoperable primary, metastatic or residual disease after surgery or at high risk of recurrence after complete resection, histologically confirmed adult soft tissue sarcoma, entered the study. The dose and schedule of the chemotherapy agents were epidoxorubicin 30 mg/m2 days 1, 2, 3, dacarbazine 300 mg/m2 days 1, 2, 3, and ifosfamide 2500 mg/m2 with mesna uroprotection days 1, 2, 3. G-CSF, 300 μg/day subcutaneously, was administered from day 7 for a maximum of 14 days and discontinued when WBC was greater than 10 x 109/L. Courses were repeated 'as soon as possible,' but never earlier than 10 days from the previous course and at least 48 hours after the last G-CSF injection. Results: A total of 66 EID + G-CSF courses were administered. A G3 and G4 (WHO) neutropenia occurred in 66% of evaluables courses. Nonhematological toxicity was mild. The median number of G-CSF injections required during any interval between courses was 9 (range: 4-14 injections) and the median interval between courses was 21 days (range: 13-36 days). The median dose intensity at the third course of chemotherapy was 1.15 (range: 0.71-1.62). Conclusion. This study shows that G-CSF allows a moderate increase in the delivered dose intensity of chemotherapy with an acceptable toxicity. Further studies are needed to investigate if this increase in DI may translate into an improved response rate.

Original languageEnglish
Pages (from-to)78-81
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume19
Issue number1
DOIs
Publication statusPublished - Feb 1996

Fingerprint

Epirubicin
Dacarbazine
Ifosfamide
Granulocyte Colony-Stimulating Factor
Sarcoma
Drug Therapy
Neutropenia
Injections
Mesna
Appointments and Schedules
Recurrence
Infection

Keywords

  • Accelerated treatment
  • G-CSF
  • Soft tissue sarcomas

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas. / Michelotti, Andrea; Romanini, Antonella; Giannessi, Piergiorgio; Bengala, Carmelo; Conte, Pierfranco.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 19, No. 1, 02.1996, p. 78-81.

Research output: Contribution to journalArticle

Michelotti, Andrea ; Romanini, Antonella ; Giannessi, Piergiorgio ; Bengala, Carmelo ; Conte, Pierfranco. / Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1996 ; Vol. 19, No. 1. pp. 78-81.
@article{e836ced69cb642de97745f78ae58e6cd,
title = "Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas",
abstract = "Background. Neutropenia and infections are the dose-limiting toxicities of the EID regimen and can cause dose reduction and/or delay in chemotherapy administration. The purpose of this study was to verify if EID + G-CSF is feasible with an acceptable toxicity in a day hospital setting and if G-CSF could allow an increase in the dose intensity of the EID regimen by shortening the intervals between the courses. Patients and Methods: 20 patients with inoperable primary, metastatic or residual disease after surgery or at high risk of recurrence after complete resection, histologically confirmed adult soft tissue sarcoma, entered the study. The dose and schedule of the chemotherapy agents were epidoxorubicin 30 mg/m2 days 1, 2, 3, dacarbazine 300 mg/m2 days 1, 2, 3, and ifosfamide 2500 mg/m2 with mesna uroprotection days 1, 2, 3. G-CSF, 300 μg/day subcutaneously, was administered from day 7 for a maximum of 14 days and discontinued when WBC was greater than 10 x 109/L. Courses were repeated 'as soon as possible,' but never earlier than 10 days from the previous course and at least 48 hours after the last G-CSF injection. Results: A total of 66 EID + G-CSF courses were administered. A G3 and G4 (WHO) neutropenia occurred in 66{\%} of evaluables courses. Nonhematological toxicity was mild. The median number of G-CSF injections required during any interval between courses was 9 (range: 4-14 injections) and the median interval between courses was 21 days (range: 13-36 days). The median dose intensity at the third course of chemotherapy was 1.15 (range: 0.71-1.62). Conclusion. This study shows that G-CSF allows a moderate increase in the delivered dose intensity of chemotherapy with an acceptable toxicity. Further studies are needed to investigate if this increase in DI may translate into an improved response rate.",
keywords = "Accelerated treatment, G-CSF, Soft tissue sarcomas",
author = "Andrea Michelotti and Antonella Romanini and Piergiorgio Giannessi and Carmelo Bengala and Pierfranco Conte",
year = "1996",
month = "2",
doi = "10.1097/00000421-199602000-00016",
language = "English",
volume = "19",
pages = "78--81",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas

AU - Michelotti, Andrea

AU - Romanini, Antonella

AU - Giannessi, Piergiorgio

AU - Bengala, Carmelo

AU - Conte, Pierfranco

PY - 1996/2

Y1 - 1996/2

N2 - Background. Neutropenia and infections are the dose-limiting toxicities of the EID regimen and can cause dose reduction and/or delay in chemotherapy administration. The purpose of this study was to verify if EID + G-CSF is feasible with an acceptable toxicity in a day hospital setting and if G-CSF could allow an increase in the dose intensity of the EID regimen by shortening the intervals between the courses. Patients and Methods: 20 patients with inoperable primary, metastatic or residual disease after surgery or at high risk of recurrence after complete resection, histologically confirmed adult soft tissue sarcoma, entered the study. The dose and schedule of the chemotherapy agents were epidoxorubicin 30 mg/m2 days 1, 2, 3, dacarbazine 300 mg/m2 days 1, 2, 3, and ifosfamide 2500 mg/m2 with mesna uroprotection days 1, 2, 3. G-CSF, 300 μg/day subcutaneously, was administered from day 7 for a maximum of 14 days and discontinued when WBC was greater than 10 x 109/L. Courses were repeated 'as soon as possible,' but never earlier than 10 days from the previous course and at least 48 hours after the last G-CSF injection. Results: A total of 66 EID + G-CSF courses were administered. A G3 and G4 (WHO) neutropenia occurred in 66% of evaluables courses. Nonhematological toxicity was mild. The median number of G-CSF injections required during any interval between courses was 9 (range: 4-14 injections) and the median interval between courses was 21 days (range: 13-36 days). The median dose intensity at the third course of chemotherapy was 1.15 (range: 0.71-1.62). Conclusion. This study shows that G-CSF allows a moderate increase in the delivered dose intensity of chemotherapy with an acceptable toxicity. Further studies are needed to investigate if this increase in DI may translate into an improved response rate.

AB - Background. Neutropenia and infections are the dose-limiting toxicities of the EID regimen and can cause dose reduction and/or delay in chemotherapy administration. The purpose of this study was to verify if EID + G-CSF is feasible with an acceptable toxicity in a day hospital setting and if G-CSF could allow an increase in the dose intensity of the EID regimen by shortening the intervals between the courses. Patients and Methods: 20 patients with inoperable primary, metastatic or residual disease after surgery or at high risk of recurrence after complete resection, histologically confirmed adult soft tissue sarcoma, entered the study. The dose and schedule of the chemotherapy agents were epidoxorubicin 30 mg/m2 days 1, 2, 3, dacarbazine 300 mg/m2 days 1, 2, 3, and ifosfamide 2500 mg/m2 with mesna uroprotection days 1, 2, 3. G-CSF, 300 μg/day subcutaneously, was administered from day 7 for a maximum of 14 days and discontinued when WBC was greater than 10 x 109/L. Courses were repeated 'as soon as possible,' but never earlier than 10 days from the previous course and at least 48 hours after the last G-CSF injection. Results: A total of 66 EID + G-CSF courses were administered. A G3 and G4 (WHO) neutropenia occurred in 66% of evaluables courses. Nonhematological toxicity was mild. The median number of G-CSF injections required during any interval between courses was 9 (range: 4-14 injections) and the median interval between courses was 21 days (range: 13-36 days). The median dose intensity at the third course of chemotherapy was 1.15 (range: 0.71-1.62). Conclusion. This study shows that G-CSF allows a moderate increase in the delivered dose intensity of chemotherapy with an acceptable toxicity. Further studies are needed to investigate if this increase in DI may translate into an improved response rate.

KW - Accelerated treatment

KW - G-CSF

KW - Soft tissue sarcomas

UR - http://www.scopus.com/inward/record.url?scp=0029670628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029670628&partnerID=8YFLogxK

U2 - 10.1097/00000421-199602000-00016

DO - 10.1097/00000421-199602000-00016

M3 - Article

VL - 19

SP - 78

EP - 81

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -